$EVAX

Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.

Evaxion Biotech (EVAX) has expanded its AI-Immunology platform to target autoimmune diseases, adding to its focus on cancer and infectious diseases. The company is testing a tolerogenic vaccine and an autoantibody binder, with initial data to be presented at a summit in November 2026. Evaxion believes its platform could offer more effective and safer treatments than current options, potentially opening new partnerships and commercial opportunities.

Evaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.

Analysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.

Evaxion A/S (EVAX) reported a Q2 2026 net loss of $3.7M, improving from the prior year. Cash reserves totaled $14M, extending runway into 2H 2027. The company advanced its cancer and infectious disease vaccine pipeline, with key data presentations and regulatory filings expected. EVAX stock rose 6.35% in pre-market trading.

Evaxion A/S (EVAX) reported Q2 2026 financial results, including a net loss of $3.7M. The company highlighted progress in its R&D pipeline, including upcoming data presentations for cancer vaccine candidates EVX-01, EVX-04, and EVX-05, as well as CMV vaccine EVX-V1. Evaxion also won the 2026 Prix Galien UK Award for Best digital health solution. The company expects its cash runway to extend into the second half of 2027.

Evaxion A/S (EVAX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides

Evaxion A/S (NASDAQ: EVAX) will release a business update and its Q2 2026 financial results on Aug. 20, 2026, before Nasdaq CM opens. Management will host a conference call and webcast at 14:30 CET/08:30 EST to present the update and results and take questions.

Evaxion A/S (NASDAQ: EVAX) will present three-year phase 2 efficacy data for personalized cancer vaccine EVX-01 at ESMO Congress 2026. The data come from an extension in advanced melanoma, including a third-year EVX-01 stand-alone arm. Prior two-year results reported ORR 75% (12/16) and 92% durable clinical benefit at two years, with no relapses.

Evaxion A/S (NASDAQ: EVAX) reported new preclinical poster data for its cytomegalovirus vaccine program EVX-V1 at IHW 2026 in Montreal. The company said AI-discovered T-cell epitopes improved control of acute infection, latency and reactivation in CMV-infected mice, complementing prior B-cell antigen results. EVX-V1 combines novel antigens with an AI-optimized gB antigen.